CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 533 enrolled
Drug / intervention
adefovir dipivoxil tabletsdrug
Likely dose
adefovir dipivoxil tablets 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00324961
NCT00324961Phase 4Completed
CompareCT.gov

A 2-year Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B

GlaxoSmithKline·interventional·Posted May 11, 2006·Updated Oct 28, 2009

In Brief

A Phase 4 clinical trial evaluating adefovir dipivoxil tablets for Chronic Hepatitis B. Completed, enrolled 533 participants across 18 sites.

Detailed Summary

This is a phase IV, 2-year, multi-center, single arm and open-label study, evaluating the efficacy and safety with using local manufactured adefovir dipivoxil in Chinese subjects with HBeAg negative chronic hepatitis B

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 11, 2006
Enrollment StartJan 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.1 years ago

Interventions

adefovir dipivoxil tabletsdrug

adefovir dipivoxil once daily 10 mg orally